%PDF-1.4
%
71 0 obj
<>
endobj
68 0 obj
<>
endobj
128 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-07T11:25:03Z
2024-03-29T00:52:34-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T00:52:34-07:00
application/pdf
Heather
200321.january
uuid:ab2022bf-1dd1-11b2-0a00-e00927fd5800
uuid:ab2022c1-1dd1-11b2-0a00-6a0000000000
endstream
endobj
57 0 obj
<>
endobj
58 0 obj
<>
endobj
72 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 41 0 R/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 43 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
31 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 51 0 R/Type/Page>>
endobj
154 0 obj
[158 0 R]
endobj
155 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.19299 Tw 9.7 0 0 10 54.3 713.1616 Tm
(kinetic analyses determined that the C)Tj
0.0005 Tc 0 Tw 6.3 0 0 6.5 211.5291 709.8616 Tm
(max)Tj
-0.00011 Tc 0.13811 Tw 9.7 0 0 10 226.6809 713.1616 Tm
[(and AUC )-54.9 (values)]TJ
0.01019 Tw -17.7712 -1.2 Td
[(were proportional to the dose administered. )54.8 (At doses between)]TJ
0.02499 Tw 0 -1.2 TD
(1.0 and 15.0 mg/kg, the serum half-life was about 13 days.)Tj
0.0815 Tw 1.2062 -1.2 Td
(Given the complexity of SLE outcome measures, and the)Tj
-0.02879 Tw -1.2062 -1.2 Td
[(low likelihood of clinical ef)17.7 (ficacy from a single dose, a formal)]TJ
-0.0011 Tw T*
[(evaluation of the ef)17.7 (ficacy of IDEC-131 was not undertaken in)]TJ
0.1006 Tw T*
[(this phase I single dose study)64.8 (. However)39.7 (, this study provides)]TJ
0.13499 Tw T*
[(the first demonstration of anti-CD40L)-348.3 (monoclonal antibody)]TJ
0.17191 Tw T*
[(administration in patients with SLE. )17.7 (This has clinical rele-)]TJ
0.0118 Tw T*
(vance because it demonstrates the feasibility of administering)Tj
0.1031 Tw T*
[(specifically tar)17.7 (geted immunosuppression, and thereby possi-)]TJ
0.1743 Tw T*
(bly reducing toxicity of treatment for autoimmune disease.)Tj
-0.0027 Tw T*
(Based on our finding that a single dose of IDEC-131 was safe)Tj
0.05251 Tw T*
(and well tolerated in patients with SLE, a multidose phase II)Tj
0.0849 Tw T*
[(study has been initiated in which the ef)17.7 (fect of IDEC-131 on)]TJ
0.00661 Tw T*
(SLE disease activity is being assessed using validated disease)Tj
0.02499 Tw T*
(activity indices.)Tj
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_0 1 Tf
0.01379 Tw 7.76 0 0 8 54.3 487.1616 Tm
(The authors thank Susan Cairelli for editorial assistance in the prepara\
tion of)Tj
0.00861 Tw 0 -1.25 TD
[(the manuscript and Dr)54.8 (. David Daikh for thoughtful review of the manuscript.)]TJ
/T1_1 1 Tf
0 Tw 9.7 0 0 10 54.3 453.1616 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 443.1616 Tm
[(1.)-875.1 (Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, )17.7 (W)79.9 (ofsy D. Long-)]TJ
1.675 -1.25 Td
(term inhibition of murine lupus by brief simultaneous blockade of)Tj
T*
(the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol)Tj
0 Tc 0 Tw T*
(1997;159:3104-8.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Mohan C, Shi )36.8 (Y)128.9 (, Laman JD, Datta SK. Interaction between CD40)]TJ
1.675 -1.25 Td
(and its ligand gp39 in the development of murine lupus nephritis. )Tj
T*
(J Immunol 1995;154:1470-80.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Janeway C Jr)39.7 (, Bottomly K. Signals and signs for lymphocyte)]TJ
1.675 -1.25 Td
(responses. Cell 1994;76:275-85.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Jenkins M. )17.7 (The ups and downs of )17.7 (T)-257.1 (cell costimulation. Immunity)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(1994;1:443-6.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Grewal I, Flavell R. CD40 and CD154 in cell-mediated immunity)64.8 (.)]TJ
1.675 -1.25 Td
[(Annu Rev Immunol 1998;16:1)36.8 (1)36.8 (1-35.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Henn )17.7 (V)128.9 (, Slupsky J, Grafe M, et al. CD40 ligand on activated)]TJ
1.675 -1.25 Td
(platelets triggers an inflammatory reaction of endothelial cells.)Tj
T*
(Nature 1998;391:591-4.)Tj
31.325 52.671 Td
[(7.)-875.1 (Armitage R, Fanslow )17.7 (W)91.8 (, Strockbine L, et al. Molecular and)]TJ
1.675 -1.25 Td
(biological characterization of a murine ligand for CD40. Nature)Tj
0 Tc 0 Tw T*
(1992;357:80-2.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (van Essen D, Kikutani H, Gray D. CD40 ligand-transduced co-)]TJ
1.675 -1.25 Td
[(stimulation of )17.7 (T)-257.1 (cells in the development of helper function. Nature)]TJ
0 Tc 0 Tw T*
(1995;378:620-3.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Noelle R, Ledbetter J, )54.8 (Aruf)17.7 (fo )54.8 (A. CD40 and its ligand, an essential)]TJ
1.675 -1.25 Td
(ligand-receptor pair for thymus-dependent B-cell activation.)Tj
0 Tc 0.0072 Tw T*
[(Immunol T)70 (oday )-17.8 (1992;13:431-3.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Koshy M, Ber)17.7 (ger D, Crow MK. Increased expression of CD40)]TJ
2.175 -1.25 Td
(ligand on systemic lupus erythematosus lymphocytes. J Clin Invest)Tj
0 Tc 0 Tw T*
(1996;98:826-37.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Datta SK, Kalled SL. CD40-CD40 ligand interaction in)]TJ
2.1381 -1.25 Td
[(autoimmune disease. )54.8 (Arthritis Rheum 1997;40:1735-45.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Desai-Mehta )54.8 (A, Lu L, Ramsey-Goldman R, Datta SK.)]TJ
2.175 -1.25 Td
[(Hyperexpression of CD40 ligand by B and )17.7 (T)-257.1 (cells in human lupus)]TJ
T*
(and its role in pathogenic autoantibody production. J Clin Invest)Tj
0 Tc 0 Tw T*
(1996;97:2063-73.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Kato K, Santana-Sahagun E, Rassenti L, et al. )17.7 (The soluble CD40)]TJ
2.175 -1.25 Td
(ligand sCD154 in systemic lupus erythematosus. J Clin Invest)Tj
0 Tc 0 Tw T*
(1999;104:947-55.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (V)110.8 (akkalanka R, )17.7 (W)79.9 (oo C, Kirou K, Koshy M, Ber)17.7 (ger D, Crow M.)]TJ
2.175 -1.25 Td
(Elevated levels and functional capacity of soluble CD40 ligand in)Tj
T*
[(systemic lupus erythematosus sera. )54.8 (Arthritis Rheum 1999;)]TJ
0 Tc 0 Tw T*
(42:871-81.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Foy )17.7 (T)74 (,)-0.1 ( )54.8 (Aruf)17.7 (fo )54.8 (A, Bajorath J, Buhlmann, Noelle R. Immune)]TJ
2.175 -1.25 Td
[(regulation by CD40 and its ligand GP39. )54.8 (Ann Rev Immunol)]TJ
0 Tc 0 Tw T*
(1996;14:591-617.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Durie F)79.7 (,)-0.1 ( Foy )17.7 (T)74 (, Masters S, Laman J, Noelle R. )17.7 (The role of CD40 in)]TJ
2.175 -1.25 Td
[(the regulation of humoral and cell-mediated immunity)64.8 (. Immunol)]TJ
0 Tc T*
[(T)70 (oday 1994;15:406-1)36.9 (1.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875.1 (T)69.9 (an EM, Cohen )54.8 (AS, Fries J, et al. )17.7 (The 1982 revised criteria for the)]TJ
2.175 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (Hochber)17.7 (g M. Updating the )54.8 (American College of Rheumatology)]TJ
2.175 -1.25 Td
(revised criteria for the classification of systemic lupus)Tj
T*
[(erythematosus [letter]. )54.8 (Arthritis Rheum 1997;40:1725.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (Grewal I, Borrow P)110.7 (, Pamer E, Oldstone M, Flavell R. )17.7 (The CD40-)]TJ
2.175 -1.25 Td
(CD154 system in anti-infective host defense. Current Opin)Tj
T*
(Immunol 1997;9:491-7.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Davis, et al: )17.7 (Antibody therapy for SLE)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(101)Tj
ET
0 0 0 0 k
/GS0 gs
100.72 59.08 407.5 -10.83 re
f*
0.5 w
100.72 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
106.328 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
51 0 obj
<>stream
8;Z\6!KP&O#ikq,j?"`3(e@8'68N='_5:tt'#;L10XnIg/#0ls?i$j3Op=/rY6eR]
l`nBU*W(]l^STFq)!A8dY@>P51WG*SXX6a#_k;I=Q/R0"?`FFFRTT&\%H;"N+>-U-
(tNW6T3^i>P0sYRHc>,F,
c1Zj4grU"c"r(R[58L*r19s6\[)EK#[Z8=CUoVFUfU.&khL1&3"?4R(MX7CM.b,HU
Q1Itk#m?>E;.C`PYORK?d&?#nYhFJIGgUep[BG0@O8#0EcUim9-qlBteZ#ob`ZFAh
3Yr/WSL/+n;Je[B:
)[p\u/A!fH6#/Kb-f7A)$2UT"%:_p^l9Ss\^_JNV1A:*KikQ>_YX2ug^)YPEe^.2f
rO%OcfaLTVQK#WEdam"#f%/F'p2`\,gZ.DPj">Ro:gKZQHhserhZ/3)!OM~>
endstream
endobj
55 0 obj
[/Indexed/DeviceRGB 255 54 0 R]
endobj
54 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
78 0 obj
<>
endobj
94 0 obj
<>
endobj
74 0 obj
<>
endobj
113 0 obj
<>
endobj
133 0 obj
<>
endobj
75 0 obj
<>
endobj
103 0 obj
<>stream
HT{PSg˽HBVU-UE, IG !gYTǢQ/Tu.3ngg?v̙oo~3pwX T,_Q :s8We&ֳ#VY5';5H9gq[A4c:=F8]s,Q,Sv}.]Ѣ~E*B,%'ʒwNH`d\baJlHKݬdLJب1KdɬR'WF%1dXڷjC>[jbsH[a1u, θV[UzuyZN5*i>CmlN;Or|oͩ>SAӶLgؕ
ۗeL#1Ɍbib*ƿ {g٫{
q%UVnQ}DQ)O33t~."Cз8AI!9q~/#3*ڌƶ6Q&S*e9& oz _ʄ%D~[|;#RNKU]izי``x+~U